Merck Trials Manufacturing Agreement With China’s Huahai Pharmaceutical
SHANGHAI - Zhejiang Huahai Pharmaceutical and Merck have entered into a trial manufacturing services agreement, the Chinese firm announced
More from Archive
More from Scrip
• By
The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.
• By
The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.
• By
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.